Virology
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • Indications
      Dosage & Administration
      Efficacy & Safety
      Study Designs
      Map pin symbol
      Maviret logo

      PRESCRIBE 8 WEEKS OF MAVIRET

      FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS1

      Map pin symbol
      Maviret logo

      PRESCRIBE 8 WEEKS OF MAVIRET

      FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS1

      STRONG • FAST • BROAD

      STRONG

      98% CURE^ RATES# across GT 1–62
      ^Cure defined as HCV RNA below the lower limit of detection at 12 weeks post end-of-treatment (SVR12).
      #98% cure rate (n/N=943/965) (based on pooled data) for GT 1–6 treatment-naïve and GT 1, 2, 4–6 pegIFN, RBV, and/or sofosbuvir experienced non-cirrhotic adult patients with 8 weeks of therapy.2

      FAST

      8-WEEK REGIMEN for GT 1–6 treatment-naïve, non-cirrhotic patients1


      BROAD
       

      ALL GENOTYPES (GT 1-6)1

      MAVIRET SAFETY CONSIDERATIONS:1

      • Evaluate for the presence of cirrhosis. MAVIRET is contraindicated in patients with moderate and severe hepatic impairment (Child-Pugh B and Child-Pugh C).
      • Patients with serologic evidence of current or past hepatitis B virus (HBV) infection should be monitored and treated according to current clinical practice guidelines to manage potential HBV reactivation. Consider initiation of HBV antiviral therapy, if indicated.
      • Consider concomitant medications for risk of drug–drug interactions. Refer to the Product Information for contraindications and interactions and the University of Liverpool HEP Drug Interactions Checker at hep-druginteractions.org
      • In clinical trials most adverse reactions were of mild severity.
        • The most common adverse reactions (≥5% of patients) were headache, fatigue and nausea
        • 0.1% discontinuation rate due to adverse reactions across all trials

      For full safety information refer to the Product Information

      MAVIRET DRUG-DRUG INTERACTIONS1,3

      Please visit hep-druginteractions.org and refer to the Product Information to check for drug-drug interactions with MAVIRET.

      NO CLINICALLY SIGNIFICANT INTERACTIONNOT RECOMMENDEDCONTRAINDICATED
      OmeprazoleDarunavir-, efavirenz- and
      lopinavir/ritonavir-containing products      		Dabigatran etexilate
      BuprenorphineSt. John’s WortRifampicin
      MethadoneCarbamazepineAtazanavir-containing products
       LovastatinAtorvastatin and simvastatin
       Cyclosporin >100 mg/dayEthinyl oestradiol-containing products

      Adapted from MAVIRET Product Information.1

      This is not a complete list. Some medications may require dose adjustment – please see below and consult the University of Liverpool HEP Drug Interactions Checker.


      Dose adjustments of select co-administered drugs1

      •Digoxin – reduce digoxin dose by 50%

      •Pravastatin – reduce pravastatin dose by 50%

      •Rosuvastatin – rosuvastatin dose should not exceed 10 mg

       

      The University of Liverpool Drug Interaction tool predicts no clinically significant interactions are expected when MAVIRET is co-administered with antacids.3

      Visit hep-druginteractions.org/checker and refer to the MAVIRET Product Information to check for drug-drug interactions.

      MANAGEMENT OF HCV FOR PRESCRIBERS

      HCV Treating For Prescribers

      MANAGEMENT OF HCV FOR CORRECTIONAL FACILITIES

      HCV Treating for Correctional Facilities

      MANAGEMENT OF HCV FOR DRUG AND ALCOHOL TREATMENT SERVICES

      HCV Treating for Drug and Alcohol Treatment Services

      MANAGEMENT OF HCV FOR NURSES

      HCV Treating for Nurses

      PBS Information

      Maviret: Authority required. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      Maviret PI

      REFERENCES: 1. MAVIRET Approved Product Information. 2. Puoti M et al. J Hepatol 2018;69(2):293–300. 3. University of Liverpool. HEP drug interactions. Available at: hep-druginteractions.org. Accessed: October 2022.

      AU-MAVI-220154. December 2022.